These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 7911181)

  • 1. Arthropathy in thalassaemia patients receiving deferiprone.
    Berkovitch M; Laxer RM; Inman R; Koren G; Pritzker KP; Fritzler MJ; Olivieri NF
    Lancet; 1994 Jun; 343(8911):1471-2. PubMed ID: 7911181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiographic and MRI features of deferiprone-related arthropathy of the knees in patients with beta-thalassemia.
    Kellenberger CJ; Schmugge M; Saurenmann T; Di Gennaro L; Eber SW; Willi UV; Babyn PS
    AJR Am J Roentgenol; 2004 Oct; 183(4):989-94. PubMed ID: 15385291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deferiprone-related arthropathy of the knee in a thalassemic patient: report of a case and review of the literature.
    Vlachaki E; Tselios K; Perifanis V; Tsatra I; Tsayas I
    Clin Rheumatol; 2008 Nov; 27(11):1459-61. PubMed ID: 18663554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.
    Barman Balfour JA; Foster RH
    Drugs; 1999 Sep; 58(3):553-78. PubMed ID: 10493280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmaco/ferrokinetic-related pro-oxidant activity of deferiprone in beta-thalassemia.
    Jirasomprasert T; Morales NP; Limenta LM; Sirijaroonwong S; Yamanont P; Wilairat P; Fucharoen S; Chantharaksri U
    Free Radic Res; 2009 May; 43(5):485-91. PubMed ID: 19353420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety profile of the oral iron chelator deferiprone: a multicentre study.
    Cohen AR; Galanello R; Piga A; Dipalma A; Vullo C; Tricta F
    Br J Haematol; 2000 Feb; 108(2):305-12. PubMed ID: 10691860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurological Complications and Cataract in a Child With Thalassemia Major Treated With Deferiprone.
    Parakh N; Sharma R; Prakash O; Mahto D; Dhingra B; Sharma S; Chandra J
    J Pediatr Hematol Oncol; 2015 Oct; 37(7):e433-4. PubMed ID: 26165407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arthropathy in thalassaemia patients receiving deferiprone.
    al-Refaie FN; Wonke B; Hoffbrand AV
    Lancet; 1994 Jul; 344(8917):262-3. PubMed ID: 7913175
    [No Abstract]   [Full Text] [Related]  

  • 9. Results of long-term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators.
    al-Refaie FN; Hershko C; Hoffbrand AV; Kosaryan M; Olivieri NF; Tondury P; Wonke B
    Br J Haematol; 1995 Sep; 91(1):224-9. PubMed ID: 7577638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.
    Olivieri NF; Brittenham GM; McLaren CE; Templeton DM; Cameron RG; McClelland RA; Burt AD; Fleming KA
    N Engl J Med; 1998 Aug; 339(7):417-23. PubMed ID: 9700174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deferiprone: new preparation. Poorly assessed.
    Prescrire Int; 2000 Oct; 9(49):131-5. PubMed ID: 11603411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone.
    Cohen AR; Galanello R; Piga A; De Sanctis V; Tricta F
    Blood; 2003 Sep; 102(5):1583-7. PubMed ID: 12763939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromosomal aberration frequencies in patients with thalassaemia major undergoing therapy with deferiprone and deferoxamine in a comparative crossover study.
    Marshall R; Tricta F; Galanello R; Leoni G; Kirkland D; Minto S; Spino M
    Mutagenesis; 2003 Sep; 18(5):457-63. PubMed ID: 12960415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic and Cardiac Iron-load in Children on Long-term Chelation with Deferiprone for Thalassemia Major.
    Totadri S; Bansal D; Trehan A; Khadwal A; Bhatia A; Sodhi KS; Bhatia P; Jain R; Das R; Khandelwal N
    Indian Pediatr; 2018 Jul; 55(7):573-575. PubMed ID: 30129538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron chelation therapy.
    Hoffbrand AV; Wonke B
    J Intern Med Suppl; 1997; 740():37-41. PubMed ID: 9350180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety Profile of Oral Iron Chelator Deferiprone in Chinese Children with Transfusion-Dependent Thalassaemia.
    Botzenhardt S; Sing CW; Wong IC; Chan GC; Wong LY; Felisi M; Rascher W; Ceci A; Neubert A
    Curr Drug Saf; 2016; 11(2):137-44. PubMed ID: 26419768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune function in patients with beta thalassaemia receiving the orally active iron-chelating agent deferiprone.
    Loebstein R; Dalal I; Nisbet-Brown E; Berkovitch M; Meydan N; Andrews D; Loubser MD; Koren G; Roifman CM; Olivieri NF
    Br J Haematol; 1997 Sep; 98(3):597-600. PubMed ID: 9332313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolated thrombocytopenia associated with hydroxyurea/deferiprone (L1) therapy in a sickle beta thalassemia patient.
    Sheikh-Taha M; Koussa S; Taher A
    Haematologica; 2006 Jun; 91(6 Suppl):ECR25. PubMed ID: 16785128
    [No Abstract]   [Full Text] [Related]  

  • 19. A multi-center safety trial of the oral iron chelator deferiprone.
    Cohen A; Galanello R; Piga A; Vullo C; Tricta F
    Ann N Y Acad Sci; 1998 Jun; 850():223-6. PubMed ID: 9668543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial.
    Agarwal MB; Gupte SS; Viswanathan C; Vasandani D; Ramanathan J; Desai N; Puniyani RR; Chhablani AT
    Br J Haematol; 1992 Oct; 82(2):460-6. PubMed ID: 1419829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.